Equities

Propanc Biopharma Inc

PPCB:PKC

Propanc Biopharma Inc

Actions
  • Price (USD)0.0003
  • Today's Change0.00 / 0.00%
  • Shares traded2.77m
  • 1 Year change-97.25%
  • Beta1.9756
Data delayed at least 15 minutes, as of Nov 21 2024 17:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.87m
  • Incorporated2010
  • Employees1.00
  • Location
    Propanc Biopharma Inc302/6 Butler Street, CamberwellMELBOURNE 3124AustraliaAUS
  • Phone+61 39882-0780
  • Fax+61 39208-4110
  • Websitehttps://www.propanc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Health Advance Inc-100.00bn-100.00bn122.62k3.00--0.0284----------0.0212----------------------------0.0356--100.00---21.75------
Seelos Therapeutics Inc2.01m4.09m170.02k8.000.0024----0.0844156.15156.1522.91-135.500.2823--6.51134,266.7057.34-180.05---386.76----203.13-9,612.88---608.33--------48.48------
Propanc Biopharma Inc0.00-1.87m236.97k1.00---------0.0372-0.03720.00-0.0060.00-------1,495.00-4,082.63---------------2.55--------35.61------
CNBX Pharmaceuticals Inc230.08k-1.21m284.67k2.00------1.24-0.0458-0.04580.0081-0.07890.6201----115,040.00-325.63-73.32---99.8014.96---525.10-3,970.88---1.34------111.900.3497------
Neximmune Inc0.00-20.62m334.72k6.00--0.4807-----18.59-18.590.000.660.00----0.00-140.56-115.07-224.94-165.07------------0.00------48.25---44.65--
Regenerative Medical Technology Grop Inc2.87m-10.15m334.79k1.00------0.1165-0.8144-0.81440.2303-2.070.5424--76.15---191.67-192.08----68.9560.24-353.35-821.490.0257-0.0755----57.49116.97-76.03--149.35--
GlobeStar Therapeutics Corp0.00-1.98m348.88k-----------0.0023-0.00230.00-0.00150.00-------38,103.72-4,657.88-------7,790.20---2,834,410.00---21.00---------31.01------
Data as of Nov 21 2024. Currency figures normalised to Propanc Biopharma Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.